Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SOD2 RNAi
- Development stage
- Preclinical
- Lead developer
- National Health Research Institutes
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
SOD2 RNAi refers to the use of RNA interference (RNAi) technology to silence the expression of Superoxide Dismutase 2 (SOD2), a mitochondrial enzyme that converts superoxide radicals into hydrogen peroxide. In the context of oncology, specifically glioblastoma, SOD2 is often upregulated in glioma stem cells (GSCs) and contributes to resistance against chemotherapy (like temozolomide) by scavenging reactive oxygen species (ROS). By knocking down SOD2, researchers aim to increase intracellular ROS levels, inhibit the stemness properties of cancer cells, and re-sensitize them to therapeutic agents. Preclinical studies have demonstrated that SOD2 RNAi can enhance apoptosis and reduce tumor proliferation in patient-derived xenograft models.
- Other names
- SOD2 RNA interferenceSOD-2 RNA interferenceSOD 2 RNA interferenceSOD2 knockdownSOD-2 knockdownSOD 2 knockdown
02
Targets
Superoxide dismutase 2 mRNA
Beyond the preview
Go deeper on SOD2 RNAi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SOD2 RNAi.